Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors in Acute Myocardial Infarction Without Heart Failure
-
Published:2024-08
Issue:
Volume:
Page:
-
ISSN:0002-9343
-
Container-title:The American Journal of Medicine
-
language:en
-
Short-container-title:The American Journal of Medicine
Author:
Kim Jihoon,
Kang Danbee,
Park Hyejeong,
Park Taek Kyu,
Lee Joo Myung,
Yang Jeong Hoon,
Song Young Bin,
Choi Jin-Ho,
Choi Seung-Hyuk,
Gwon Hyeon-Cheol,
Guallar Eliseo,
Cho Juhee,
Hahn Joo-YongORCID
Reference30 articles.
1. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril;Ferrari;Expert Rev Cardiovasc Ther,2005
2. Effects of an angiotensin-converting–enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients;N Engl J Med,2000
3. Telmisartan, ramipril, or both in patients at high risk for vascular events;Yusuf;N Engl J Med,2008
4. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both;Pfeffer;N Engl J Med,2003
5. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis;Caldeira;Am J Cardiovasc Drugs,2012